文献速递泌尿男性生殖肿瘤

整合治疗中改良格拉斯哥预后评分与影像学预测转移性肾细胞癌的缓解与结局

Integrating On-Treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma.
PubMed 文献 · JAMA Oncol · 2023-01-01

该事后分析基于III期IMmotion151(发现队列)和II期IMmotion150(验证队列),评估治疗中改良格拉斯哥预后评分(mGPS)对接受阿替利珠单抗(联合贝伐珠单抗)或舒尼替尼治疗的转移性肾细胞癌患者缓解与结局的预测价值。在IMmotion150中,治疗中mGPS最早可在治疗开始后6周预测结局;在两个试验中,治疗中mGPS均提供独立于影像学缓解的预后信息,疾病控制亚组中其C指数优于IRC-RECIST。作者认为这些数据支持将治疗中mGPS与影像学分期整合用于更全面、以患者为中心的低成本治疗监测。

要点

  • 在IMmotion150中,治疗中mGPS最早可在治疗开始后6周预测结局。
  • 两个试验中,治疗中mGPS均提供独立于首次影像学评估缓解的预后信息。
  • 疾病控制亚组中,治疗中mGPS的C指数为0.651,高于IRC-RECIST的0.574。

核心结论

  • 这些数据支持将治疗中mGPS与影像学分期整合,以低成本为转移性肾细胞癌患者实现更全面、以患者为中心的治疗监测。

研究设计与样本

  • 事后分析于2022年10月至2023年4月进行,评估治疗中mGPS在接受阿替利珠单抗(联合贝伐珠单抗)或舒尼替尼治疗的转移性肾细胞癌患者中的预后与预测性能。
  • 发现队列为III期IMmotion151研究,验证队列为II期IMmotion150研究。

主要发现

  • IMmotion151发现队列共915例转移性肾细胞癌患者,其中861例有基线mGPS,691例有治疗中mGPS。
  • IMmotion150验证队列共305例转移性肾细胞癌患者,其中199例可评估治疗中mGPS。
  • 在IMmotion150中,治疗中mGPS最早可在治疗开始后6周预测结局,为早期治疗调整提供窗口。
  • 两个临床试验中,治疗中mGPS均提供有价值的预后信息,且不依赖于首次分期时影像学评估的治疗缓解。
  • 在疾病控制亚组中(611例有IRC-RECIST数据),治疗中mGPS的C指数为0.651(95%CI 0.588-0.714),优于IRC-RECIST的0.574(95%CI 0.528-0.619),并提供独立预后信息。

临床怎么用

  • 作者认为这些数据支持将治疗中mGPS与影像学分期整合,用于转移性肾细胞癌患者的治疗监测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In the era of immuno-oncology, imaging alone seems to be insufficient to capture treatment responses, as patients with stable disease treated with immunotherapy have a wide range of clinical outcomes. There is an unmet need for complementary (ideally cost-efficient) markers that enable assessment of therapy response and outcomes in conjunction with imaging. OBJECTIVES: To examine whether longitudinal changes in the modified Glasgow prognostic score (mGPS), which is based on C-reactive protein and albumin, can predict responses and outcomes in patients with metastatic renal cell carcinoma (mRCC). DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis, conducted from October 2022 to April 2023, evaluated the prognostic and predictive performance of on-treatment mGPS in patients with mRCC being treated with atezolizumab (plus bevacizumab) or sunitinib in 2 randomized clinical trials: the phase 3 IMmotion151 study (discovery cohort) and the phase 2 IMmotion150 study (validation cohort). MAIN OUTCOMES AND MEASURES: Outcomes were investigator-assessed progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 and overall survival (OS) for survival analyses. To compare the prognostic value of the on-treatment mGPS with radiologic staging, we used RECIST assessed by the Independent Review Committee (IRC-RECIST) to ensure high data quality. RESULTS: Of the 915 patients with mRCC in the IMmotion151 discovery cohort, baseline mGPS was available for 861 patients and on-treatment mGPS for 691. The IMmotion150 validation cohort included 305 patients with mRCC, and on-treatment mGPS could be evaluated for 199. In the IMmotion150 study, on-treatment mGPS predicted outcomes as early as 6 weeks following therapy initiation, thereby opening a window for early therapy adjustments. In both clinical trials, on-treatment mGPS provided valuable prognostic information regardless of imaging-assessed treatment response at first staging. Of note, in the disease control subgroup, on-treatment mGPS exhibited superior and independent prognostic information compared with IRC-RECIST (available for 611 patients; C-index, 0.651 [95% CI, 0.588-0.714] for the mGPS during treatment vs 0.574 [95% CI, 0.528-0.619] for IRC-RECIST). CONCLUSIONS AND RELEVANCE: These data support the concept of integrating on-treatment mGPS for more holistic and patient-centered therapy monitoring in addition to radiologic staging to improve clinical care at a low cost for patients with mRCC.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Saal J, Bald T, Eckstein M, et al. Integrating On-Treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma. JAMA Oncol. 2023. PMID: 37347489. doi:10.1001/jamaoncol.2023.1822

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。